Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Lowered by Zacks Research

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Thursday, Zacks reports.

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 22nd. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $67.67.

Prestige Consumer Healthcare Trading Up 0.7%

Shares of NYSE:PBH opened at $49.08 on Thursday. The company has a market capitalization of $2.33 billion, a PE ratio of 11.03, a P/E/G ratio of 1.53 and a beta of 0.34. The company has a current ratio of 3.23, a quick ratio of 1.99 and a debt-to-equity ratio of 1.06. Prestige Consumer Healthcare has a 12-month low of $42.62 and a 12-month high of $71.07. The business’s fifty day simple moving average is $48.54 and its 200-day simple moving average is $54.20.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. The company had revenue of $265.71 million during the quarter, compared to analysts’ expectations of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. Prestige Consumer Healthcare’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, equities research analysts predict that Prestige Consumer Healthcare will post 4.56 earnings per share for the current fiscal year.

Institutional Trading of Prestige Consumer Healthcare

Large investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Prestige Consumer Healthcare during the 2nd quarter valued at about $370,187,000. Dimensional Fund Advisors LP lifted its stake in Prestige Consumer Healthcare by 3.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company’s stock worth $158,414,000 after purchasing an additional 91,710 shares in the last quarter. Rice Hall James & Associates LLC acquired a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth approximately $32,602,000. The Manufacturers Life Insurance Company acquired a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth approximately $31,135,000. Finally, Bank of America Corp DE acquired a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth approximately $26,277,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.